Retatrutide is an investigational medication being developed by Eli Lilly and Company for obesity, overweight and several related metabolic conditions. It is particularly notable because it activates three hormone receptors at the same time: GLP-1, GIP, and glucagon.BUY RETATRUTIDE ONLINE USA
As of August 2026, retatrutide is not FDA-approved and is not legally available for routine public use. It remains an investigational medicine in Phase 3 development. Lilly says it plans to submit a Biologics License Application to the FDA in Q1 2027.
1. What exactly is retatrutide?
Retatrutide is a once-weekly injectable triple receptor agonist. Rather than acting on only one metabolic pathway, it simultaneously activates:
- GLP-1 receptors
- GIP receptors
- Glucagon receptors
This is why it is sometimes informally called a “GLP-3” drug. However, “GLP-3” is not a scientifically recognized drug class; triple agonist is the more accurate description
2. How does retatrutide work?
Retatrutide’s three receptor targets have different effects.
GLP-1
GLP-1 signaling can:
- Increase glucose-dependent insulin secretion
- Reduce glucagon secretion
- Slow gastric emptying
- Increase feelings of fullness
- Reduce appetite
- Help improve blood-glucose control
This pathway is also targeted by medications such as semaglutide. BUY RETATRUTIDE ONLINE USA
GIP
GIP can influence:
- Insulin secretion
- Glucose metabolism
- Appetite and energy balance
- Fat metabolism
